- Home
- RFI vs CERS Comparison
RFI vs CERS Comparison
Compare RFI & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFI
- CERS
- Stock Information
- Founded
- RFI 1992
- CERS 1991
- Country
- RFI United States
- CERS United States
- Employees
- RFI N/A
- CERS N/A
- Industry
- RFI Investment Managers
- CERS EDP Services
- Sector
- RFI Finance
- CERS Technology
- Exchange
- RFI Nasdaq
- CERS Nasdaq
- Market Cap
- RFI 349.2M
- CERS 324.3M
- IPO Year
- RFI N/A
- CERS 1997
- Fundamental
- Price
- RFI $12.71
- CERS $1.68
- Analyst Decision
- RFI
- CERS Buy
- Analyst Count
- RFI 0
- CERS 3
- Target Price
- RFI N/A
- CERS $3.17
- AVG Volume (30 Days)
- RFI 69.8K
- CERS 1.9M
- Earning Date
- RFI 01-01-0001
- CERS 10-30-2024
- Dividend Yield
- RFI 8.25%
- CERS N/A
- EPS Growth
- RFI N/A
- CERS N/A
- EPS
- RFI N/A
- CERS N/A
- Revenue
- RFI N/A
- CERS $176,229,000.00
- Revenue This Year
- RFI N/A
- CERS $26.47
- Revenue Next Year
- RFI N/A
- CERS $11.48
- P/E Ratio
- RFI N/A
- CERS N/A
- Revenue Growth
- RFI N/A
- CERS 14.71
- 52 Week Low
- RFI $9.62
- CERS $1.38
- 52 Week High
- RFI $12.52
- CERS $2.59
- Technical
- Relative Strength Index (RSI)
- RFI 45.93
- CERS 46.20
- Support Level
- RFI $12.51
- CERS $1.63
- Resistance Level
- RFI $12.72
- CERS $2.03
- Average True Range (ATR)
- RFI 0.22
- CERS 0.11
- MACD
- RFI -0.01
- CERS -0.01
- Stochastic Oscillator
- RFI 30.98
- CERS 31.37
About RFI Cohen & Steers Total Return Realty Fund Inc.
Cohen & Steers Total Return Realty Fund Inc is a diversified, closed-end management investment company. Its investment objective is to achieve a high total return through investment in real estate securities. The Fund invests majority of its total assets in the equity securities of real estate companies under normal circumstances, which includes common shares, REITs, rights or warrants, convertible securities, and preferred shares.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.